Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination

Martin de la Presa, Amit Govil, Winston D. Chamberlain, Edward J. Holland

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Purpose: The purpose of this study was to report a case of acute corneal epithelial rejection of living-related conjunctival limbal allograft (LR-CLAL) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Observations: A 27-year-old woman developed acute epithelial rejection of LR-CLAL 2 weeks after receiving the SARS-CoV-2 vaccine. She received the LR-CLAL transplant 4 years and 7 months previously and had a stable clinical course with no history of rejection. She had an ABO blood group and human leukocyte antigen compatible donor, no systemic comorbidities, and no rejection risk factors. Conclusions: The novel SARS-CoV-2 vaccine upregulates the immune system to produce an adaptive immune response. The SARS-CoV-2 vaccine may potentially be associated with increased risk of rejection in those with ocular surface transplants.

Original languageEnglish (US)
Pages (from-to)252-253
Number of pages2
Issue number2
StatePublished - Feb 1 2022


  • COVID-19
  • Rejection
  • SARS-CoV-2
  • Transplant
  • Vaccine

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Acute Corneal Epithelial Rejection of LR-CLAL After SARS-CoV-2 Vaccination'. Together they form a unique fingerprint.

Cite this